Induction of HEXIM1 activities by HMBA derivative 4a1: Functional consequences and mechanism.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer Letters

• Publication date

  2016-08-28

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.canlet.2016.05.029PMID 27238569PMCID PMC4988685
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma.

  2016cited by this paper
• HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist

  2015cited by this paper
• Development of a Fluorescent Reporter System to Delineate Cancer Stem Cells in Triple‐Negative Breast Cancer

  2015cited by this paper
• HEXIM1 plays a critical role in the inhibition of the androgen receptor by anti-androgens.

  2014cited by this paper
• Brd4 and HEXIM1: Multiple Roles in P-TEFb Regulation and Cancer

  2014cited by this paper
• Lead optimization of HMBA to develop potent HEXIM1 inducers.

  2014cited by this paper
• Release of Positive Transcription Elongation Factor b (P-TEFb) from 7SK Small Nuclear Ribonucleoprotein (snRNP) Activates Hexamethylene Bisacetamide-inducible Protein (HEXIM1) Transcription*

  2014cited by this paper
• Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells.

  2013cited by this paper
• HEXIM1 down-regulates hypoxia-inducible factor-1α protein stability.

  2013cited by this paper
• Inducible re-expression of HEXIM1 causes physiological cardiac hypertrophy in the adult mouse.

  2013cited by this paper
• Solid Tumor Differentiation Therapy – Is It Possible?

  2012cited by this paper
• Identification of HEXIM1 as a Positive Regulator of p53*

  2012cited by this paper
• Inhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesis

  2012cited by this paper
• HEXIM1 is a critical determinant of the response to tamoxifen

  2011cited by this paper
• HEXIM1 modulates vascular endothelial growth factor expression and function in breast epithelial cells and mammary gland

  2010cited by this paper
• DHT selectively reverses Smad3-mediated/TGF-beta-induced responses through transcriptional down-regulation of Smad3 in prostate epithelial cells.

  2010cited by this paper
• A 2009 update on the treatment of patients with hormone receptor-positive breast cancer.

  2009cited by this paper
• p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo

  2009cited by this paper
• Resistance to antiestrogen arzoxifene is mediated by overexpression of cyclin D1.

  2009cited by this paper
• Mutation of the HEXIM 1 Gene Results in Defects During Heart and Vascular Development Partly Through Downregulation of Vascular Endothelial Growth Factor

  2008cited by this paper
• Hexamethylene Bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF-κB activity: Implications for cancer therapy

  2008cited by this paper
• Mutation of the HEXIM1 Gene Results in Defects During Heart and Vascular Development Partly Through Downregulation of Vascular Endothelial Growth Factor

  2008cited by this paper
• HEXIM1 regulates 17beta-estradiol/estrogen receptor-alpha-mediated expression of cyclin D1 in mammary cells via modulation of P-TEFb.

  2008cited by this paper
• Predictors of response to aromatase inhibitors.

  2007cited by this paper
• Increased HEXIM1 expression during erythroleukemia and neuroblastoma cell differentiation

  2006influential reference
• Modulation of a P-TEFb Functional Equilibrium for the Global Control of Cell Growth and Differentiation

  2006cited by this paper
• The breast cell growth inhibitor, estrogen down regulated gene 1, modulates a novel functional interaction between estrogen receptor alpha and transcriptional elongation factor cyclin T1

  2005cited by this paper
• Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.

  2005cited by this paper
• HEXIM1 forms a transcriptionally abortive complex with glucocorticoid receptor without involving 7SK RNA and positive transcription elongation factor b.

  2005cited by this paper
• Binding of the 7SK snRNA turns the HEXIM1 protein into a P‐TEFb (CDK9/cyclin T) inhibitor

  2004cited by this paper
• Animal Model Progression to Malignancy in the Polyoma Middle T Oncoprotein Mouse Breast Cancer Model Provides a Reliable Model for Human Diseases

  2003cited by this paper
• Identification of a novel inhibitor of breast cell growth that is down-regulated by estrogens and decreased in breast tumors.

  2003cited by this paper
• Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA.

  2003cited by this paper
• P-TEFb, a Cyclin-Dependent Kinase Controlling Elongation by RNA Polymerase II

  2000cited by this paper
• HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance.

  2000cited by this paper
• Tamoxifen in the Treatment of Breast Cancer

  1998cited by this paper
• Tamoxifen in the treatment of breast cancer.

  1998cited by this paper
• The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens.

  1997cited by this paper
• Cell cycle control by steroid hormones.

  1994cited by this paper
• Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent.

  1992cited by this paper
• Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).

  1989cited by this paper
• Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.

  1988cited by this paper
• Tamoxifen in the treatment of breast cancer.

  1988cited by this paper

• HMBA ameliorates obesity by MYH9‐ and ACTG1‐dependent regulation of hypothalamic neuropeptides

  2023cites this paper
• Overexpression Bombyx mori HEXIM1 Facilitates Immune Escape of Bombyx mori Nucleopolyhedrovirus by Suppressing BmRelish-Driven Immune Responses

  2022cites this paper
• Breast cancer stem cells: A review of their characteristics and the agents that affect them

  2021cites this paper
• Non-epigenetic induction of HEXIM1 by DNMT1 inhibitors and functional relevance

  2020cites this paper
• Inhibition of the histone demethylase, KDM5B, directly induces re-expression of tumor suppressor protein HEXIM1 in cancer cells

  2019cites this paper
• Phosphorylation of the histone demethylase KDM5B and regulation of the phenotype of triple negative breast cancer

  2019cites this paper
• Hexim1, an RNA-controlled protein hub

  2018cites this paper
• This information is current as STING Infections by Inducing Type I IFN through Adjuvant during Intracellular Bacterial Anti-Cancer Drug HMBA Acts as an Yunn

  2017cites this paper
• Anti-Cancer Drug HMBA Acts as an Adjuvant during Intracellular Bacterial Infections by Inducing Type I IFN through STING

  2017cites this paper
• HMBA is a putative HSP70 activator stimulating HEXIM1 expression that is down-regulated by estrogen.

  2017cites this paper